phrykt

Enveric Biosciences, Inc. (ENVB): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of ENVB were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No ENVB insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ENVB short interest

Low short interest. 0.4% of ENVB shares are sold short: about 1 share in 228. Over the last 12 reports the number of shares short went down 83%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 19,617 ENVB shares were sold short, 0.4% of the shares outstanding, down 49.3% from the report before. At the average daily volume of 35,170 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.44%May 15Oct 307.02%

Days to cover

1.0May 15Oct 301.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202619,6170.44%-49%35,1701.0
Oct 15, 202638,7020.86%+151%73,4791.0
Sep 30, 202615,4350.34%-33%80,5911.0
Sep 15, 202622,8720.51%+78%44,9641.0
Aug 31, 202612,8730.29%-25%159,5381.0
Aug 14, 202617,2620.39%-10%115,6771.0
Jul 31, 202619,1131.01%+3%140,4861.0
Jul 15, 202618,5130.98%+18%77,7111.0
Jun 30, 202615,6750.83%-66%142,7011.0
Jun 15, 202646,3312.45%+74%270,1361.0
May 29, 202626,5831.41%-77%194,7651.0
May 15, 2026115,9746.14%-87%402,8181.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Enveric Biosciences company events

Enveric Biosciences filed 13 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Aug 14, 2026.

  1. Aug 14, 2026ResultsReleased financial results. Filing
  2. Jun 9, 2026AnnouncementEnveric Biosciences, Inc. filed a prospectus supplement to offer an additional $2.42 million of shares of its common stock, par value $0.01 per share, issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC, dated April 9, 2025. Filing
  3. Jun 9, 2026AnnouncementShared information with investors. Filing
  4. May 29, 2026LeadershipThe Compensation Committee recommended, and the Board of Directors of Enveric Biosciences, Inc. approved and adopted, (i) a new form of Restricted Stock Unit Award Agreement and (ii) a new form of Restricted Stock Award Agreement (the “RSA Agreement”, and together with the RSU Agreement, the “Award… Filing
  5. May 15, 2026ResultsReleased financial results. Filing
  6. Apr 30, 2026AnnouncementEnveric Biosciences, Inc., a Delaware corporation, filed a definitive proxy statement on Schedule 14A with the Securities and Exchange Commission for the 2026 Annual Meeting of Stockholders of the Company, which will be held on Thursday, May 28, 2026, at 10:00 a.m., Eastern Time. Filing
  7. Apr 20, 2026AgreementEnveric Biosciences, Inc., a Delaware corporation, entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell to the Investors in a private placement (i) 98,000 shares of the Company’s common stock, par value $0.01 per… Filing
  8. Mar 27, 2026ResultsReleased financial results. Filing
  9. Feb 6, 2026AnnouncementEnveric Biosciences, Inc. filed a prospectus supplement to register an additional $1.35 million of shares of its common stock, par value $0.01 per share, issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC, dated April 9, 2025. Filing
  10. Jan 28, 2026AgreementEnveric Biosciences, Inc., a Delaware corporation, entered into a securities purchase agreement with certain institutional investors (each, an “Investor”), pursuant to which the Company agreed to issue and sell to the Investors in a registered direct offering, an aggregate of 328,802 shares of the… Filing
  11. Jan 9, 2026AnnouncementShared information with investors. Filing
  12. Dec 12, 2025AgreementEnveric Biosciences, Inc., a Delaware corporation entered into warrant exercise inducement offer letters with certain institutional investors that held certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having… Filing
  13. Dec 11, 2025VoteReported shareholder vote results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Enveric Biosciences financials

Famous investors that hold ENVB

1 of the 50 well-known investors we track reported holding ENVB in their latest 13F filing. The largest position is Ken Griffin's, worth $60.8K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202641,372$60.8K0.0%+196%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ENVB in the last 120 days.

FiledHolderFormStake
Nov 3, 2026Sio Capital Management, LLC13G7.4%
Nov 3, 2026Sio Capital Management, LLC13G7.4%

Questions about Enveric Biosciences, Inc. (ENVB) stock

Are ENVB insiders buying or selling?

No ENVB insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in ENVB?

As of Oct 30, 2026, 19,617 ENVB shares were sold short, 0.4% of the shares outstanding, down 49.3% from the report before. At the average daily volume of 35,170 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold ENVB?

1 of the 50 well-known investors we track reported ENVB in their latest 13F filing, including Ken Griffin. The largest position is worth $60.8K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.